- Home
- NVCR vs GLPG Comparison
NVCR vs GLPG Comparison
Compare NVCR & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVCR
- GLPG
- Stock Information
- Founded
- NVCR 2000
- GLPG 1999
- Country
- NVCR Switzerland
- GLPG Belgium
- Employees
- NVCR N/A
- GLPG N/A
- Industry
- NVCR Medical/Dental Instruments
- GLPG Biotechnology: Pharmaceutical Preparations
- Sector
- NVCR Health Care
- GLPG Health Care
- Exchange
- NVCR Nasdaq
- GLPG Nasdaq
- Market Cap
- NVCR 1.9B
- GLPG 1.8B
- IPO Year
- NVCR 2015
- GLPG 2005
- Fundamental
- Price
- NVCR $19.11
- GLPG $28.76
- Analyst Decision
- NVCR Buy
- GLPG Sell
- Analyst Count
- NVCR 6
- GLPG 4
- Target Price
- NVCR $32.83
- GLPG $25.33
- AVG Volume (30 Days)
- NVCR 941.3K
- GLPG 487.2K
- Earning Date
- NVCR 07-24-2025
- GLPG 04-23-2025
- Dividend Yield
- NVCR N/A
- GLPG N/A
- EPS Growth
- NVCR N/A
- GLPG N/A
- EPS
- NVCR N/A
- GLPG N/A
- Revenue
- NVCR $621,711,000.00
- GLPG $311,493,731.00
- Revenue This Year
- NVCR $5.56
- GLPG $0.78
- Revenue Next Year
- NVCR $9.15
- GLPG N/A
- P/E Ratio
- NVCR N/A
- GLPG N/A
- Revenue Growth
- NVCR 18.27
- GLPG 18.32
- 52 Week Low
- NVCR $14.17
- GLPG $22.36
- 52 Week High
- NVCR $34.13
- GLPG $31.23
- Technical
- Relative Strength Index (RSI)
- NVCR 58.46
- GLPG 64.87
- Support Level
- NVCR $18.66
- GLPG $28.16
- Resistance Level
- NVCR $20.06
- GLPG $29.20
- Average True Range (ATR)
- NVCR 0.86
- GLPG 0.80
- MACD
- NVCR 0.19
- GLPG 0.11
- Stochastic Oscillator
- NVCR 71.98
- GLPG 84.81
About NVCR NovoCure Limited
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing medicines. The company is committed to improving patients' lives world-wide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan. It derives maximum revenue from United States of America.